News

Stockholm3 developer Henrik Grönberg named Cancer Researcher of the Year

Professor Henrik Grönberg is awarded the Swedish Cancer Foundation’s Cancer Researcher of the Year 2022 for his research that enables early detection of prostate cancer. Henrik Grönberg’s research has led to the test Stockholm3. The Cancer Foundation’s research committee, chaired by former chairman of the Nobel Committee, Klas…

Fast track publication of the STHLM3 MRI trial in The Lancet Oncology

Stockholm3 in combination with MRI enables implementation of population-based screening of prostate cancer The combination decreases unnecessary biopsies by 74% STOCKHOLM, August 13, 2021. A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast tracked and is now published in the…

Stockholm3 abstract wins 1st prize at European Association of Urology

An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69% compared to Standard…

A3P Biomedical recruits new CEO to lead commercial expansion

STOCKHOLM, June 18, 2021. A3P Biomedical appoints David Rosén as new CEO to lead the commercial expansion of the company’s novel Stockholm3 test for early detection of prostate cancer.  David brings more than 20 years’ experience from the medical device industry, including senior international positions at Getinge and Cantel…

A3P Biomedical strengthens the management team for international expansion

STOCKHOLM, January 10, 2021. A3P Biomedical strengthens the management team with Marianne Waplan as CFO, Marcela Björn as Director of Marketing & Sales and Malin Gidlund as Head of Lab Operations preparing for the company’s international expansion. “In order to realize A3P Biomedical’s growth opportunities, we are building a…

A3P Biomedical raises SEK 110 million in growth capital

A3P Biomedical announced today that it has raised SEK 110 million in growth capital from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test. Near-term, A3P will focus on accelerating the Nordic launch, as well as preparing commercialization in Europe and North…

A3P Biomedical reports strong evidence for Stockholm3 in major Norwegian real-life study

A3P Biomedical announced today that a real-life study including 4,784 men has been carried out by Stavanger University Hospital showing that the company’s blood-based Stockholm3 test leads to a 28% reduction in prostate cancer work-up, an increase in identification of clinically significant cancers by 55% and reduction of direct…

St Görans Sjukhus erbjuder Stockholm3 som del av rutindiagnostik

Bor du i Stockholm och vill ta Stockholm3 testet kan du vända dig till St Görans Sjukhus. Du behöver inte en remiss och det kostar inte mer än den vanliga patientavgiften. Här är länken till prostatacancercentrum på St Göran sjukhus. Prostatacancercentrum på S:t Görans sjukhus har som mål att vara Sveriges ledande…

Stockholm3 leder till genombrott inom diagnostik av prostatacancer

Prostatacancercentrum Capio S:t Göran har infört prostatacancerdiagnostik med Stockholm3-testet och riktad vävnadsprovtagning. De kliniska resultaten ses som ett genombrott inom diagnostik av prostatacancer eftersom man hittar mer än dubbelt så många män med aggressiv prostatacancer och samtidigt minskar antalet onödiga…